Hereditary Breast and Ovarian Cancer Syndrome

Description

This case-based course describes the cancer risks associated with hereditary mutations in BRCA1 and BRCA2 genes, risk reducing approaches, and cascade genetic testing for family members. The impact of germline BRCA mutations on cancer treatment selection is also discussed. In addition, the course provides an overview of other hereditary syndromes associated with breast and other cancers, such as Li-Fraumeni syndrome and Cowden syndrome.

Learning Objectives

After participating in this activity, learners will be better able to:

  • Describe diagnostic evaluation of a patient with suspected hereditary breast-ovarian cancer syndrome
  • Compare and contrast the impact of germline BRCA status on treatment selection for women with early vs. metastatic, HER2-negative breast cancer
  • Evaluate cancer risks associated with various high-penetrance hereditary breast cancer syndromes and discuss appropriate screening and prevention strategies
  • Recognize the benefits of germline testing of unaffected family members
  • Apply knowledge gained to counsel germline BRCA mutation carriers regarding cancer treatment and risk-reduction approaches

Faculty

  • Claudine Isaacs, MD, FRCPC
    Georgetown University

Disclosures

ASCO and Conquer Cancer gratefully acknowledge the following companies for their support of the Hereditary Breast and Ovarian Cancer Syndrome course: Genomic Health, Inc. and Illumina, Inc.

Disclaimer/Unlabeled Usage Statement

The information presented is that of the contributing authors and does not necessarily represent the views of the American Society of Clinical Oncology. Specific therapies discussed may not be approved and/or specified for use as indicated. Therefore, before prescribing any medication, please review the complete prescribing information including indications, contraindications, warnings, precautions and adverse effects.

New content added regularly, don't miss out!

This site is intended for healthcare professionals in France, Germany, Italy, Japan and the United Kingdom only.

The selection of ASCO content on this site was made by the ASCO Publication and Education teams. Springer Healthcare selected the experts for interview. All content is made available solely for educational and informational purposes and personal use only.

© 2021 American Society of Clinical Oncology (ASCO®). All Rights Reserved.

This program is supported by an educational grant from Daiichi Sankyo and brought to you by Springer Healthcare | Contact Us | Privacy Policy

We'd love your feedback!

Before you go please let us have your feedback...